Autotaxin: a Potential Biomarker for Breast Cancer.

Last updated: January 25, 2023
Sponsor: Ankara Etlik City Hospital
Overall Status: Completed

Phase

N/A

Condition

Breast Cancer

Cancer

Treatment

N/A

Clinical Study ID

NCT05680311
autotaxin1
  • Ages 18-80
  • Female
  • Accepts Healthy Volunteers

Study Summary

The goal of this clinical trial is to test the efficiency of Autotaxin (ATX) as a biomarker for breast cancer patients.

The main questions it aims to answer are;

  • is ATX a reliable tumor marker for breast cancer patients in diagnosis

  • can ATX differentiate cancer patients from non-cancer ones

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Preoperatively diagnosed breast cancer patients with no synchronous cancer and withoutknown hepatic or other inflammatory disorders.

Exclusion

Exclusion Criteria:

  • Patients with benign breast diseases and no known cancer history.

Study Design

Total Participants: 110
Study Start date:
January 01, 2019
Estimated Completion Date:
March 15, 2021

Study Description

80 breast cancer patients and 30 normal patients with no known cancer history were enrolled in this study. All patients were female. The mean ages of cancer patients were 58.2 and 52.7 consecutively for cancer and non-cancer patients. The mean serum ATX levels of cancer and non-cancer patients were 1570.72 and 121.86 ng/mL consecutively (p=0.001). The cut-off value of ATX serum level was 178.49ng/mL according to the ROC analysis. The area under the ROC curve was 0.901showing that ATX is very efficient in distinguishing between two diagnostic groups (diseased/normal). ATX also showed good correlations with known tumor markers (CEA, CA15-3, CA125 levels). ATX levels were still higher than the cut-off value even in cancer patients with normal or low classical tumor marker levels.

Connect with a study center

  • Ankara Etlik City Hospital

    Ankara, 06170
    Turkey

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.